Office of the Director, National Institutes of Health; Notice of Meeting, 14863 [2016-06075]
Download as PDF
Federal Register / Vol. 81, No. 53 / Friday, March 18, 2016 / Notices
asabaliauskas on DSK3SPTVN1PROD with NOTICES
to patients. Instead, between
approximately July 11, 2008 and
September 3, 2008, Mr. McQuerry
deposited over $2,300 of gift checks into
his personal bank account. He
additionally used the gift checks to
make direct purchases at various
retailers. Mr. McQuerry’s fraud resulted
in a loss of approximately $200,098 to
the pharmaceutical company.
As a result of this conviction, FDA
sent Mr. McQuerry by certified mail on
October 30, 2015, a notice proposing to
permanently debar him from providing
services in any capacity to a person that
has an approved or pending drug
product application. The proposal was
based on a finding, under section
306(a)(2)(A) and (a)(2)(B) of the FD&C
Act, that Mr. McQuerry was convicted
of a felony under Federal law for
conduct relating to the development or
approval, including the process for
development or approval, of a drug
product, and conduct otherwise relating
to the regulation of a drug product
under the FD&C Act. The proposal also
offered Mr. McQuerry an opportunity to
request a hearing, providing him 30
days from the date of receipt of the letter
in which to file the request, and advised
him that failure to request a hearing
constituted a waiver of the opportunity
for a hearing and of any contentions
concerning this action. Mr. McQuerry
did not request a hearing and has,
therefore, waived his opportunity for a
hearing and any contentions concerning
his debarment (21 CFR part 12).
approved or pending drug product
application who knowingly employs or
retains as a consultant or contractor, or
otherwise uses the services of Wesley A.
McQuerry, in any capacity during his
debarment, will be subject to civil
money penalties (section 307(a)(6) of the
FD&C Act (21 U.S.C. 335b(a)(6))). If Mr.
McQuerry provides services in any
capacity to a person with an approved
or pending drug product application
during his period of debarment, he will
be subject to civil money penalties
(section 307(a)(7) of the FD&C Act). In
addition, FDA will not accept or review
any abbreviated new drug applications
from Wesley A. McQuerry during his
period of debarment (section
306(c)(1)(B) of the FD&C Act.
Any application by Mr. McQuerry for
special termination of debarment under
section 306(d)(4) of the FD&C Act
should be identified with Docket No.
FDA–2015–N–3225 and sent to the
Division of Dockets Management (see
ADDRESSES). All such submissions are to
be filed in four copies. The public
availability of information in these
submissions is governed by 21 CFR
10.20.
Publicly available submissions may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
II. Findings and Order
Therefore, the Director, Office of
Enforcement and Import Operations,
Office of Regulatory Affairs, under
sections 306(a)(2)(A) and (a)(2)(B) of the
FD&C Act, under authority delegated to
him (Staff Manual Guide 1410.35), finds
that Wesley A. McQuerry has been
convicted of a felony under Federal law
for conduct relating to the development
or approval, including the process for
development or approval, of a drug
product and conduct otherwise relating
to the regulation of a drug product
under the FD&C Act.
As a result of the foregoing finding,
Wesley A. McQuerry is permanently
debarred from providing services in any
capacity to a person with an approved
or pending drug product application
under sections 505, 512, or 802 of the
FD&C Act (21 U.S.C. 355, 360b, or 382),
or under section 351 of the Public
Health Service Act (42 U.S.C. 262),
effective (see DATES) (see section
201(dd), 306(c)(1)(B), and
306(c)(2)(A)(ii) of the FD&C Act, (21
U.S.C. 321(dd), 335a(c)(1)(B), and
335a(c)(2)(A)(ii)). Any person with an
[FR Doc. 2016–06104 Filed 3–17–16; 8:45 am]
VerDate Sep<11>2014
19:50 Mar 17, 2016
Jkt 238001
Dated: March 11, 2016.
Armando Zamora,
Deputy Director, Office of Enforcement and
Import Operations, Office of Regulatory
Affairs.
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Advisory Committee on Research on
Women’s Health.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Advisory Committee
on Research on Women’s Health.
Date: April 19, 2016.
Time: 9:00 a.m. to 4:00 p.m.
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
14863
Agenda: The Committee serves to advise
and make recommendations to the Director,
Office of Research on Women’s Health
(ORWH) on a broad range of topics.
Information is also available on the
Institute’s/Center’s home page: https://orwh.
od.nih.gov/about/acrwh/index.asp where an
agenda and any additional information for
the meeting will be posted when available.
Place: National Institutes of Health,
Building 31, Room 6C, 31 Center Drive,
Bethesda, MD 20892.
Contact Person: Terri L. Cornelison, MD,
Ph.D., Associate Director for Clinical
Research, Office of Research on Women’s
Health, Office of the Director, 6707
Democracy Blvd., Bethesda, MD 20817, 301–
402–1770, cornelit@od.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
www4.ordh.od.nih.gov/, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: March 14, 2016.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–06075 Filed 3–17–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
E:\FR\FM\18MRN1.SGM
18MRN1
Agencies
[Federal Register Volume 81, Number 53 (Friday, March 18, 2016)]
[Notices]
[Page 14863]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-06075]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, National Institutes of Health; Notice of
Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Advisory Committee on Research on Women's Health.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: Advisory Committee on Research on Women's
Health.
Date: April 19, 2016.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: The Committee serves to advise and make recommendations
to the Director, Office of Research on Women's Health (ORWH) on a
broad range of topics. Information is also available on the
Institute's/Center's home page: https://orwh.od.nih.gov/about/acrwh/index.asp where an agenda and any additional information for the
meeting will be posted when available.
Place: National Institutes of Health, Building 31, Room 6C, 31
Center Drive, Bethesda, MD 20892.
Contact Person: Terri L. Cornelison, MD, Ph.D., Associate
Director for Clinical Research, Office of Research on Women's
Health, Office of the Director, 6707 Democracy Blvd., Bethesda, MD
20817, 301-402-1770, cornelit@od.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: www4.ordh.od.nih.gov/, where an agenda and any additional
information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.14,
Intramural Research Training Award; 93.22, Clinical Research Loan
Repayment Program for Individuals from Disadvantaged Backgrounds;
93.232, Loan Repayment Program for Research Generally; 93.39,
Academic Research Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187,
Undergraduate Scholarship Program for Individuals from Disadvantaged
Backgrounds, National Institutes of Health, HHS)
Dated: March 14, 2016.
Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-06075 Filed 3-17-16; 8:45 am]
BILLING CODE 4140-01-P